फलो गर्नुहोस्
Englishनेपाली
← पछाडि
औषधि · अन्तरक्रिया

Topiramate — अन्तरक्रिया (Interactions)

अन्य औषधि, खाना र जडीबुटी उत्पादनले Topiramate को काम बदल्न सक्छन्। यस पृष्ठका सबै कुरा Topiramate कै FDA-स्वीकृत लेबलबाट आएका हुन् — मुख्य गाइडकै स्रोतबाट।

← पूरा Topiramate गाइडमा फर्कनुहोस्

⚠ सावधानी: • Contraceptives: decreased contraceptive efficacy and increased breakthrough bleeding, especially at doses greater than 200 mg/day . • Monitor lithium levels if lithium is used with high-dose topiramate oral solution .

Topiramate को लेबलमा नाम भएका औषधिहरू

लेबलले जसरी समूह बनाएको छ, त्यसरी नै राखिएको छ। प्रत्येक नाम त्यस औषधिको NepalDoc गाइडसँग जोडिन्छ; लेबलले औषधिको नाम नभई वर्ग मात्र भनेको ठाउँमा लेबलकै शब्द उद्धृत गरिएको छ।

लेबलको खण्ड 7.1

Antiepileptic Drugs Concomitant administration of phenytoin or carbamazepine with topiramate resulted in a clinically significant decrease in plasma concentrations of topiramate when compared to topiramate given alone. A dosage adjustment may be needed .

Other Carbonic Anhydrase Inhibitors

Concomitant use of topiramate oral solution, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., zonisamide or acetazolamide) may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation.

CNS Depressants

Concomitant administration of topiramate and alcohol or other CNS depressant drugs has not been evaluated in clinical studies.

लेबलको खण्ड 7.4

Contraceptives The possibility of decreased contraceptive efficacy and increased breakthrough bleeding may occur in patients taking contraceptive products with topiramate oral solution. Patients taking estrogen containing or progestin-only contraceptives should be asked to report any change in their bleeding patterns.

Hydrochlorothiazide (HCTZ)

Topiramate C max and AUC increased when HCTZ was added to topiramate. The clinical significance of this change is unknown. The addition of HCTZ to topiramate may require a decrease in the topiramate dose .

लेबलको खण्ड 7.6

Pioglitazone A decrease in the exposure of pioglitazone and its active metabolites were noted with the concurrent use of pioglitazone and topiramate in a clinical trial.

लेबलको खण्ड 7.7

Lithium An increase in systemic exposure of lithium following topiramate doses of up to 600 mg/day can occur. Lithium levels should be monitored when co-administered with high dose topiramate .

Amitriptyline Some

Patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patient's clinical response and not on the basis of plasma levels .

Topiramate को लेबलले ८ औषधिको नाम लिएको छ, जुन NepalDoc मा पनि छन्।

यहाँ नाम भएका औषधिका अन्तरक्रिया पृष्ठहरू

यहाँ नाम भएका यी औषधिका आफ्नै अन्तरक्रिया पृष्ठ पनि छन्:

लेबलमा खाना, पेय र जडीबुटी

मदिरा (Alcohol)

7.3 CNS Depressants Concomitant administration of topiramate and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of topiramate to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse reactions, topiramate oral solution should be used with extreme caution if used in combination with alcohol and other CNS depressants.

Topiramate को लेबलको पूरा अन्तरक्रिया खण्ड पढ्नुहोस्

• Contraceptives: decreased contraceptive efficacy and increased breakthrough bleeding, especially at doses greater than 200 mg/day . • Monitor lithium levels if lithium is used with high-dose topiramate oral solution .

7.1 Antiepileptic Drugs Concomitant administration of phenytoin or carbamazepine with topiramate resulted in a clinically significant decrease in plasma concentrations of topiramate when compared to topiramate given alone. A dosage adjustment may be needed . Concomitant administration of valproic acid and topiramate has been associated with hypothermia and hyperammonemia with and without encephalopathy. Examine blood ammonia levels in patients in whom the onset of hypothermia has been reported .

7.2 Other Carbonic Anhydrase Inhibitors Concomitant use of topiramate oral solution, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., zonisamide or acetazolamide) may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation. Therefore, patients given topiramate oral solution concomitantly with another carbonic anhydrase inhibitor should be monitored particularly closely for the appearance or worsening of metabolic acidosis .

7.3 CNS Depressants Concomitant administration of topiramate and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of topiramate to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse reactions, topiramate oral solution should be used with extreme caution if used in combination with alcohol and other CNS depressants.

7.4 Contraceptives The possibility of decreased contraceptive efficacy and increased breakthrough bleeding may occur in patients taking contraceptive products with topiramate oral solution. Patients taking estrogen containing or progestin-only contraceptives should be asked to report any change in their bleeding patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough bleeding .

7.5 Hydrochlorothiazide (HCTZ) Topiramate C max and AUC increased when HCTZ was added to topiramate. The clinical significance of this change is unknown. The addition of HCTZ to topiramate may require a decrease in the topiramate dose .

7.6 Pioglitazone A decrease in the exposure of pioglitazone and its active metabolites were noted with the concurrent use of pioglitazone and topiramate in a clinical trial. The clinical relevance of these observations is unknown; however, when topiramate is added to pioglitazone therapy or pioglitazone is added to topiramate therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state .

7.7 Lithium An increase in systemic exposure of lithium following topiramate doses of up to 600 mg/day can occur. Lithium levels should be monitored when co-administered with high dose topiramate .

7.8 Amitriptyline Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patient's clinical response and not on the basis of plasma levels .

Topiramate गाइड · सबै अन्तरक्रिया पृष्ठहरू · औषधि A–Z

स्रोतU.S. FDA-approved label via DailyMed (label effective 13 Mar 2026) · NepalDoc medicine catalog · अमेरिकी लेबलिङ नेपालको DDA-स्वीकृत लेबलिङ र स्थानीय प्रिस्क्राइबिङ अभ्यासभन्दा फरक हुन सक्छ।

यो पृष्ठले Topiramate को FDA-स्वीकृत लेबलको सारांश जानकारीका लागि दिन्छ — यो चिकित्सकीय सल्लाह होइन। तपाईंले लिने हरेक औषधि, सप्लिमेन्ट र जडीबुटी उत्पादनबारे आफ्नो डाक्टर वा फार्मासिस्टलाई सधैं भन्नुहोस्।

एपमा औषधि खोज्नुहोस् फार्मेसी खोज्नुहोस्
+ सुरक्षा जानकारी

यो पृष्ठ सामान्य जानकारीका लागि मात्र हो, चिकित्सकीय सल्लाह होइन। औषधि प्रयोग गर्नुअघि डाक्टर वा फार्मासिस्टसँग सल्लाह लिनुहोस्। विवरण माथि उल्लेखित स्रोतहरूबाट आएको हो र परिवर्तन हुन सक्छ। सूचीमा हुनुले कुनै फार्मेसीमा औषधि उपलब्ध छ भन्ने ग्यारेन्टी दिँदैन।

यो औषधि सेयर गर्नुहोस्
NepalDoc — Nepal's Healthcare Super-App (Beta) / नेपालको स्वास्थ्य सुपर-एप (बेटा).
Medicine information only — not medical advice. Confirm with a pharmacist or doctor.